I know nothing about finance but quite a lot about drug development, and there's something I can't get my head around with RVX. Any other company with a drug that has those results from BOM, a BTD from the FDA, a trial in progress in pulmonary hypertension, and stunning preclinical data on covid-19 would be swimming in money and offers from BP. And yet RVX is talking to the government of Marocco. Why?  Don must be getting good offers. If he is turning them down for reasons that are not in the company's (and patients') best interest, are the shareholders powerless to do anything about it? Do we have to just sit and watch and wonder? Can we not force an enquiry?